EDINBURGH, Scotland, Aug. 29,
2023 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC
BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage
biotechnology company developing platform allogeneic gamma-delta T
cell therapies for cancer, today announced that it will be
presenting virtually at the upcoming H.C. Wainwright event from
Monday, September
11th through Wednesday, September
13th starting at 7:00
a.m. ET.
Bryan Kobel, Chief Executive
Officer of TC BioPharm, will be giving the presentation. Management
will also be hosting in-person and virtual one-on-one meetings
during the conference.
Event: TC BioPharm at the H.C. Wainwright
25th Annual Global Investment Conference
Date: Monday, September 11th through
Wednesday, September
13th
Time: On Demand from
7:00 a.m. ET to 7:00 p.m. ET
daily
A webcast of the event will be available on the 'Events &
Presentations' section of TC BioPharm's Investor Relations website
at https://ir.tcbiopharm.com/events-presentations.
For more information on the H.C. Wainwright Conference or to
schedule a one-on-one meeting with TC BioPharm management, please
contact your conference representative or you may also email your
request to ir@tcbiopharm.com.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
gamma-delta T cell therapies for the treatment of cancer with human
efficacy data in acute myeloid leukemia. Gamma-delta T cells are
naturally occurring immune cells that embody properties of both the
innate and adaptive immune systems and can intrinsically
differentiate between healthy and diseased tissue. TC BioPharm uses
an allogeneic approach in both unmodified and CAR modified
gamma-delta T cells to effectively identify, target and eradicate
both liquid and solid tumors in cancer.
TC BioPharm is the leader in developing gamma-delta T cell
therapies, and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of
acute myeloid leukemia using the Company's proprietary allogeneic
CryoTC technology to provide frozen product to clinics worldwide.
TC BioPharm also maintains a robust pipeline for future indications
in solid tumors as well as a significant IP/patent portfolio in the
use of CARs with gamma-delta T cells and owns our manufacturing
facility to maintain cost and product quality controls.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-to-present-at-hc-wainwright-25th-annual-global-investment-conference-301912479.html
SOURCE TC BioPharm